Search Result

Results for "

Melanotan

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Apoptosis (1) Cathepsin (1) Drug Derivative (1) Integrin (2) Interleukin Related (1) Melanocortin Receptor (4) PD-1/PD-L1 (3) Radionuclide-Drug Conjugates (RDCs) (4) Somatostatin Receptor (1) TREM receptor (1)
By Research Areas:	Cancer (10) Endocrinology (1) Metabolic Disease (1) Neurological Disease (3)

Inhibitors & Agonists

Peptides

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-N2466

Melanotan I 1 Publications Verification MT-I; [Nle4,D-Phe7]-α-MSH	Melanocortin Receptor	Neurological Disease Cancer
Melanotan I is a potent non-selective melanocortin receptor (MCR) agonist. Melanotan I is a synthetic analogue of α-melanocyte stimulating hormone (α-MSH) that stimulates melanogenesis. Melanotan I can induce skin tanning by mimicking the actions of a-MSH on the melanocortin type 1 receptors (MC1R) of melanocytes. Melanotan I can be used for the research of sun-induced skin cancer, melanoma, inflammation and male erectile dysfunction .

HY-P0267

Melanotan (MT)-II 1 Publications Verification	Melanocortin Receptor	Neurological Disease
Melanotan (MT)-II, a synthetic melanocortin receptor agonist, is an injectable peptide hormone used to promote tanning.

HY-P10292

NOTA-Pep-1L	Radionuclide-Drug Conjugates (RDCs) Interleukin Related	Cancer
NOTA-Pep-1L specifically targets the IL13RA2 receptor for tumor imaging . NOTA-Pep-1L can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).

HY-N2466A

Melanotan I acetate 1 Publications Verification MT-I acetate; [Nle4,D-Phe7]-α-MSH acetate	Melanocortin Receptor	Cancer
Melanotan I acetate is a potent non-selective melanocortin receptor (MCR) agonist. Melanotan I acetate is a synthetic analogue of α-melanocyte stimulating hormone (α-MSH) that stimulates melanogenesis. Melanotan I acetate can induce skin tanning by mimicking the actions of a-MSH on the melanocortin type 1 receptors (MC1R) of melanocytes. Melanotan I acetate can be used for sunlight-induced skin cancers research .

HY-P11347

NOTA-AUNP-12	PD-1/PD-L1	Cancer
NOTA-AUNP-12 is a PD-L1 antagonist (IC₅₀=2.24×10 ⁻⁷ M). NOTA-AUNP-12 is promising for research of cancers (e.g., lung/esophageal cancers) .

HY-175323

NOTA-IMB-RGD	Integrin PD-1/PD-L1	Cancer
NOTA-IMB-RGD is a dual molecular probe targeting integrin αvβ3 and programmed death ligand-1 (PD-L1). NOTA-IMB-RGD blocks the PD-1/PD-L1 signaling pathway and integrin αvβ3-overexpressing tumor vasculature. NOTA-IMB-RGD is promising for research of solid tumors co-expressing PD-L1 and αvβ3 (e.g., glioma, breast cancer) .

HY-P10978

NK224	PD-1/PD-L1	Cancer
NK224 is a peptide-based radiotracer targeting human PD-L1, with dual-radionuclide ( ⁶⁸Ga and ¹⁸F) labeling compatibility enabled by the NOTA chelator. NK224 exhibits high binding affinity to PD-L1, with an IC₅₀ value of 2.45 nM. NK224 visualizes intrapatient tumor heterogeneity and dynamically monitors PD-L1 target occupancy during immunotherapy. NK224 can be used for the study of non-small cell lung cancer (NSCLC) .

HY-P10220

NOTA-COG1410	Radionuclide-Drug Conjugates (RDCs) TREM receptor	Cancer
NOTA-COG1410 forms triggering receptor expressed on myeloid cells 2 (TREM2) targeting ligand. NOTA-COG1410 is capable of being labelled with ⁶⁸Gallium ( ⁶⁸Ga) for discovery and diagnosis of digestive system tumors through positron emission tomography/computed tomography (PET/CT). NOTA-COG1410 can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs) .

HY-P0267A

Melanotan (MT)-II acetate	Melanocortin Receptor	Neurological Disease Metabolic Disease Endocrinology
Melanotan (MT)-II acetate is a melanocortin receptor agonist that crosses the blood-brain barrier. Melanotan (MT)-II acetate activates melanocortin receptor 3 and melanocortin receptor 4, and stimulates the release of central endogenous oxytocin. Melanotan (MT)-II acetate reverses recognition memory impairment, increased anxiety levels and reduced exploratory tendency in zebrafish exposed to short-term high-fat diet. Melanotan (MT)-II acetate improves impaired social behavior indicators in mouse models of autism spectrum disorder. Melanotan (MT)-II acetate induces weight loss, reduces food intake and exerts anorectic effects. Melanotan (MT)-II acetate increases intracavernous pressure and erectile activity in brown rats. Melanotan (MT)-II acetate can be used in studies related to memory impairment, anxiety, reduced exploratory behavior, autism spectrum disorder, obesity and erectile dysfunction .

HY-P11844

NOTA-FZCD-3	Cathepsin Radionuclide-Drug Conjugates (RDCs)	Cancer
NOTA-FZCD-3 is a NOTA (HY-134418)-labeled FZCD-3 polypeptide precursor that targets cathepsin D (CTSD) with a K_D of 0.65 μM. NOTA-FZCD-3 binds specifically to the active site of CTSD, exhibits rapid in vivo clearance properties, and remains stable in blood for more than 2 h. NOTA-FZCD-3 can be used in studies monitoring CTSD-positive tumors .

HY-P0036D

NOTA-Octreotide	Drug Derivative Radionuclide-Drug Conjugates (RDCs) Somatostatin Receptor Apoptosis	Cancer
NOTA‑Octreotide is a selective SSTR2‑targeting PET tracer. NOTA‑Octreotide binds specifically to SSTR2 and accumulates in SSTR2‑expressing tissues. NOTA‑Octreotide enables effective imaging of somatostatin receptor‑positive tumors in mice and shows high specific uptake in SSTR2‑expressing organs in healthy rats. NOTA-Octreotide can be used for PET imaging investigation of neuroendocrine tumors. .

HY-P11596

NOTA-Asp2-αvβ6L	Integrin	Cancer
NOTA-Asp2-αvβ6L is an integrin αvβ6 binder with selective accumulation in αvβ6-positive pancreatic cancer cells and tumors. NOTA-Asp2-αvβ6L can be used as a PET/CT tracer for imaging pancreatic ductal adenocarcinoma (PDAC) .

Cat. No.	Product Name	Target	Research Area

HY-N2466

Melanotan I 1 Publications Verification MT-I; [Nle4,D-Phe7]-α-MSH	Melanocortin Receptor	Neurological Disease Cancer
Melanotan I is a potent non-selective melanocortin receptor (MCR) agonist. Melanotan I is a synthetic analogue of α-melanocyte stimulating hormone (α-MSH) that stimulates melanogenesis. Melanotan I can induce skin tanning by mimicking the actions of a-MSH on the melanocortin type 1 receptors (MC1R) of melanocytes. Melanotan I can be used for the research of sun-induced skin cancer, melanoma, inflammation and male erectile dysfunction .

HY-P0267

Melanotan (MT)-II 1 Publications Verification	Melanocortin Receptor	Neurological Disease
Melanotan (MT)-II, a synthetic melanocortin receptor agonist, is an injectable peptide hormone used to promote tanning.

HY-P10292

NOTA-Pep-1L	Radionuclide-Drug Conjugates (RDCs) Interleukin Related	Cancer
NOTA-Pep-1L specifically targets the IL13RA2 receptor for tumor imaging . NOTA-Pep-1L can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).

HY-N2466A

Melanotan I acetate 1 Publications Verification MT-I acetate; [Nle4,D-Phe7]-α-MSH acetate	Melanocortin Receptor	Cancer
Melanotan I acetate is a potent non-selective melanocortin receptor (MCR) agonist. Melanotan I acetate is a synthetic analogue of α-melanocyte stimulating hormone (α-MSH) that stimulates melanogenesis. Melanotan I acetate can induce skin tanning by mimicking the actions of a-MSH on the melanocortin type 1 receptors (MC1R) of melanocytes. Melanotan I acetate can be used for sunlight-induced skin cancers research .

HY-P11347

NOTA-AUNP-12	PD-1/PD-L1	Cancer
NOTA-AUNP-12 is a PD-L1 antagonist (IC₅₀=2.24×10 ⁻⁷ M). NOTA-AUNP-12 is promising for research of cancers (e.g., lung/esophageal cancers) .

HY-175323

NOTA-IMB-RGD	Integrin PD-1/PD-L1	Cancer
NOTA-IMB-RGD is a dual molecular probe targeting integrin αvβ3 and programmed death ligand-1 (PD-L1). NOTA-IMB-RGD blocks the PD-1/PD-L1 signaling pathway and integrin αvβ3-overexpressing tumor vasculature. NOTA-IMB-RGD is promising for research of solid tumors co-expressing PD-L1 and αvβ3 (e.g., glioma, breast cancer) .

HY-P10978

NK224	PD-1/PD-L1	Cancer
NK224 is a peptide-based radiotracer targeting human PD-L1, with dual-radionuclide ( ⁶⁸Ga and ¹⁸F) labeling compatibility enabled by the NOTA chelator. NK224 exhibits high binding affinity to PD-L1, with an IC₅₀ value of 2.45 nM. NK224 visualizes intrapatient tumor heterogeneity and dynamically monitors PD-L1 target occupancy during immunotherapy. NK224 can be used for the study of non-small cell lung cancer (NSCLC) .

HY-P10220

NOTA-COG1410	Radionuclide-Drug Conjugates (RDCs) TREM receptor	Cancer
NOTA-COG1410 forms triggering receptor expressed on myeloid cells 2 (TREM2) targeting ligand. NOTA-COG1410 is capable of being labelled with ⁶⁸Gallium ( ⁶⁸Ga) for discovery and diagnosis of digestive system tumors through positron emission tomography/computed tomography (PET/CT). NOTA-COG1410 can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs) .

HY-P0267A

Melanotan (MT)-II acetate	Melanocortin Receptor	Neurological Disease Metabolic Disease Endocrinology
Melanotan (MT)-II acetate is a melanocortin receptor agonist that crosses the blood-brain barrier. Melanotan (MT)-II acetate activates melanocortin receptor 3 and melanocortin receptor 4, and stimulates the release of central endogenous oxytocin. Melanotan (MT)-II acetate reverses recognition memory impairment, increased anxiety levels and reduced exploratory tendency in zebrafish exposed to short-term high-fat diet. Melanotan (MT)-II acetate improves impaired social behavior indicators in mouse models of autism spectrum disorder. Melanotan (MT)-II acetate induces weight loss, reduces food intake and exerts anorectic effects. Melanotan (MT)-II acetate increases intracavernous pressure and erectile activity in brown rats. Melanotan (MT)-II acetate can be used in studies related to memory impairment, anxiety, reduced exploratory behavior, autism spectrum disorder, obesity and erectile dysfunction .

HY-P11844

NOTA-FZCD-3	Cathepsin Radionuclide-Drug Conjugates (RDCs)	Cancer
NOTA-FZCD-3 is a NOTA (HY-134418)-labeled FZCD-3 polypeptide precursor that targets cathepsin D (CTSD) with a K_D of 0.65 μM. NOTA-FZCD-3 binds specifically to the active site of CTSD, exhibits rapid in vivo clearance properties, and remains stable in blood for more than 2 h. NOTA-FZCD-3 can be used in studies monitoring CTSD-positive tumors .

HY-P0036D

NOTA-Octreotide	Drug Derivative Radionuclide-Drug Conjugates (RDCs) Somatostatin Receptor Apoptosis	Cancer
NOTA‑Octreotide is a selective SSTR2‑targeting PET tracer. NOTA‑Octreotide binds specifically to SSTR2 and accumulates in SSTR2‑expressing tissues. NOTA‑Octreotide enables effective imaging of somatostatin receptor‑positive tumors in mice and shows high specific uptake in SSTR2‑expressing organs in healthy rats. NOTA-Octreotide can be used for PET imaging investigation of neuroendocrine tumors. .

HY-P11596

NOTA-Asp2-αvβ6L	Integrin	Cancer
NOTA-Asp2-αvβ6L is an integrin αvβ6 binder with selective accumulation in αvβ6-positive pancreatic cancer cells and tumors. NOTA-Asp2-αvβ6L can be used as a PET/CT tracer for imaging pancreatic ductal adenocarcinoma (PDAC) .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Name
Email *

	Sorry, but the email address you supplied was invalid.